April 07, 2020
1 min read
Save

Study examines asymptomatic SARS-CoV-2 infection, Johnson & Johnson announces lead vaccine candidate — top stories in infectious disease

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Results of a small study conducted in China showed that asymptomatic infection with SARS-CoV-2 occurred most often in adults aged 30 to 49 years. It was the top story in infectious disease last week.

Another top story was about Johnson & Johnson’s lead COVID-19 vaccine candidate, which is expected to be introduced in human clinical studies by September 2020.

Read these and more top stories in infectious disease below:

Small Chinese study examines characteristics of asymptomatic infection with SARS-CoV-2

Asymptomatic infection with SARS-CoV-2, the virus that causes COVID-19, occurred most often among adults aged 30 to 49 years, according to results from a single-center study in Shenzhen, China, that was published in The Journal of Infectious Diseases. Read more.

Johnson & Johnson announces lead COVID-19 vaccine candidate

Johnson & Johnson announced the selection of a lead COVID-19 vaccine candidate from constructs it had been working on since January 2020, with expected initiation of human clinical studies by September 2020 at the latest. Read more.

Image of vaccine 
A top story in infectious disease last week was about Johnson & Johnson’s lead COVID-19 vaccine candidate, which is expected to be introduced in human clinical studies by September 2020.
Source: Adobe Stock

FDA authorizes emergency use of antimalarial drugs for COVID-19

The FDA authorized the emergency use of two antimalarial medications to treat some hospitalized patients with COVID-19. Read more.

NanoFlu shows promise in phase 3 trial among older adults

NanoFlu, a recombinant quadrivalent influenza vaccine candidate that has been granted fast track status by the FDA, met all primary endpoints in a phase 3 trial testing its efficacy and overall safety in older adults, Novavax announced. Read more.

Universal masking policy stands to protect community, ease anxiety about COVID-19

Universal masking policies have been a common topic of debate during the COVID-19 pandemic, which has now affected citizens in most countries and territories throughout the world. Some hospitals have begun implementing their own policies regarding masks. Officials are also calling on policymakers to act while experts weigh the benefits of having the general public wear masks during essential outings. Read more.